Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?
A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer
1 other identifier
interventional
230
1 country
1
Brief Summary
The purpose of this study is to compare outcomes of patients undergoing standard or extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2016
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 23, 2016
CompletedFirst Posted
Study publicly available on registry
June 1, 2016
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedNovember 23, 2021
November 1, 2021
5.3 years
May 23, 2016
November 22, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause mortality
3yrs post-operation
Secondary Outcomes (1)
all-cause mortality
1yr post-operation
Study Arms (2)
Standard resection
ACTIVE COMPARATORPancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Extended resection
EXPERIMENTALPancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16
Interventions
Pancreaticoduodenectomy:child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
Pancreaticoduodenectomy:child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
Eligibility Criteria
You may qualify if:
- Pathologic diagnosis of pancreatic ductal adenocarcinoma
- Signed the informed consents
You may not qualify if:
- Pathologic diagnosis of other pancreatic cancers
- Pre-operative anti-cancer treatment
- Recurrence patients
- Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
- Pre operative exam: Total bilirubin more than 250µmol/L
- AJCC stage IV
- Operation non radical
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruijin Hospitallead
- Shanghai Zhongshan Hospitalcollaborator
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicinecollaborator
Study Sites (1)
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, 200032, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Baiyong SHEN
Shanghai Ruijin Pancreatic Disease Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
May 23, 2016
First Posted
June 1, 2016
Study Start
July 1, 2016
Primary Completion
October 1, 2021
Study Completion
October 1, 2021
Last Updated
November 23, 2021
Record last verified: 2021-11